MedTrace Logo

SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA

NCT05848947 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-01-29

Study results available
· View outcomes & findings →

Summary

The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatocellular carcinoma.

Conditions

  • Carcinoma
  • Carcinoma, Hepatocellular
  • Liver Neoplasm

Interventions

DRUG

99mTc-Macro Albumin Aggregate

Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.

Sponsors & Collaborators

  • Bright Research Partners

    collaborator INDUSTRY

  • Sirtex Medical

    lead INDUSTRY

Principal Investigators

  • Douglas Murrey, MD · Inland Imaging

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2023-07-05
Completion
2023-07-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05848947 on ClinicalTrials.gov